The US has asked the Indian drugmaker, Ranbaxy Laboratories, to furnish details on its products eligible for reimbursements under the Medicaid program from the American Government, the company said on Wednesday. However, the company added that it is a request for documents and information and “is not an allegation of wrongdoing or demand for compensation.”